{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"SAVANNAH","nct_id":"NCT03778229","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=savannah-nct03778229. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"SAVANNAH","arms":[{"description":"osimertinib + savolitinib","label":"osimertinib + savolitinib","type":"EXPERIMENTAL"},{"description":"placebo + savolitinib","label":"placebo + savolitinib","type":"PLACEBO_COMPARATOR"}],"collaborators":["Hutchison Medipharma Limited"],"completion_date":{"date":"2026-12-31","type":"ESTIMATED"},"conditions":["Carcinoma"],"enrollment":{"count":367,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"osimertinib","otherNames":[],"type":"DRUG"},{"name":"savolitinib","otherNames":[],"type":"DRUG"},{"name":"placebo","otherNames":[],"type":"DRUG"}],"last_update":"2026-04-23","lead_sponsor":"AstraZeneca","official_title":"A Phase II Study Assessing the Efficacy of Osimertinib in Combination With Savolitinib in Patients With EGFRm+ and MET+, Locally Advanced or Metastatic Non Small Cell Lung Cancer Who Have Progressed Following Treatment With Osimertinib.","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2024-08-23","type":"ACTUAL"},"primary_outcomes":[{"measure":"Objective Response Rate (ORR) by Investigator Assessment; Target Population Analysis Set","timeFrame":"Time from randomization/first dose of study treatment to progression or last evaluable assessment in the absence of progressionuntil the end of the study, or an approximate maximum of 5.6 years."},{"measure":"Objective Response Rate (ORR) by Investigator Assessment; 300 mg QD Safety Analysis Set","timeFrame":"Time from randomization/first dose of study treatment to progression or last evaluable assessment in the absence of progression until the end of the study, or an approximate maximum of 5.6 years."}],"references":[{"citation":"de Marinis F, Kim TM, Bonanno L, Cheng S, Kim SW, Tiseo M, Chu Q, Proto C, Sacher A, Luo YH, Novello S, Hao D, Baik C, Bazhenova L, Lee JS, Cho BC, Cadranel J, Diep TB, Metro G, Narayanan P, Yoneshima Y, de Castro Carpeno J, Baldotto C, Yang JC, Sequist LV, Levy B, Hartmaier R, Igwegbe I, Poole L, Xu W, Ahn MJ. A plain language summary of the SAVANNAH study: savolitinib plus osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification whose cancer had grown or spread on osimertinib. Future Oncol. 2026 Jul;22(17):2013-2025. doi: 10.1080/14796694.2026.2692029. Epub 2026 Jul 16.","pmid":"42460617","type":"DERIVED"},{"citation":"Yang JC, Chen YM, Batra U, Do KH, Sitthideatphaiboon P, Danchaivijitr P, Lee KY, Chindaprasirt J, Yang CT, Chang GC, Charoentum C, Ungtrakul T, Moran JIH, Hartmaier R, Igwegbe I, Gont A, Haskins M, Xu W, Riess JW. Savolitinib Plus Osimertinib in Epidermal Growth Factor Receptor-Mutated, MET-Amplified Advanced Non-Small Cell Lung Cancer: A Randomized Phase II trial. Clin Lung Cancer. 2026 Jan;27(1):38-46. doi: 10.1016/j.cllc.2025.10.018. Epub 2025 Oct 22.","pmid":"41308232","type":"DERIVED"},{"citation":"Schmid S, Fruh M, Peters S. Targeting MET in EGFR resistance in non-small-cell lung cancer-ready for daily practice? Lancet Oncol. 2020 Mar;21(3):320-322. doi: 10.1016/S1470-2045(19)30859-9. Epub 2020 Feb 3. No abstract available.","pmid":"32027845","type":"DERIVED"}],"start_date":{"date":"2019-01-09","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib","url":"https://clinicaltrials.gov/study/NCT03778229"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/savannah-nct03778229"}